Targets › ADAM9
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.
Metalloprotease that cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as TEK, KDR, EPHB4, CD40, VCAM1 and CDH5. May mediate cell-cell, cell-matrix interactions and regulate the motility of cells via interactions with integrins..; FUNCTION: [Isoform 2]: May act as alpha-secretase for amyloid precursor protein (APP). (UniProt, Q13443)
Open in Phaseline: the race on ADAM9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| MacroGenics | MGC028 anti-ADAM9 antibody-drug conjugate | ADAM9 | Phase 1 | Advanced Solid Tumors | Nov 2026 |
Advanced Solid Tumors (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.